Meeting
2024 ASCO Annual Meeting
Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.
Authors
David Morgan Thomas
Centre for Molecular Oncology, University of New South Wales, Sydney, NSW, Australia
David Morgan Thomas , Gennaro Daniele , Jeong Eun Kim , Shirish M. Gadgeel , Eugene R. Ahn , Luis G. Paz-Ares , Hans Prenen , David Chen , Junhan Fang , Timothy R. Wilson , Brian P. Simmons , Fabrice Barlesi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04589845
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3092)
DOI
10.1200/JCO.2024.42.16_suppl.3092
Abstract #
3092
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
First Author: Shubham Pant
First Author: Tycel Jovelle Phillips
Poster
2022 ASCO Annual Meeting
Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.
First Author: Thierry Andre
Poster
2021 ASCO Annual Meeting
Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
First Author: Juergen Wolf